Earnings Ahead

ACRS - Aclaris Therapeutics

9.74 -0.05 -0.51

Aclaris Therapeutics

Aclaris Therapeutics

About

Profile


Headquarters

Pennsylvania, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

ACRS



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M
  • HW Wainwright cuts Aclaris to neutral, cites underwhelming study data
  • Aclaris spikes after leadership change, strategic review
  • Aclaris draws second downgrade despite Phase 2 win for eczema therapy
  • Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy
  • Aclaris posts topline data from mid-stage trial for eczema therapy
  • Aclaris to slash 46% of workforce as it reprioritizes drug programs
  • Aclaris Therapeutics announces patent license agreement with Sun Pharma for alopecia
  • Aclaris plummets as mid-stage trial for arthritis therapy fails
  • Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.07, revenue of $9.28M
  • Aclaris Therapeutics rises 13% on insider buy
  • Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.03, revenue of $1.87M misses by $0.03M
  • Aclaris Therapeutics GAAP EPS of -$0.42 beats by $0.02, revenue of $2.53M beats by $0.78M
  • Aclaris Therapeutics Q1 2023 Earnings Preview
  • Aclaris stock falls ~35% as zunsemetinib fails mid-stage study in skin disorder
  • Aclaris Therapeutics GAAP EPS of -$0.41 beats by $0.05, revenue of $7.75M beats by $5.76M
  • Goldman Sachs initiates Aclaris at Buy citing potential in lead asset
  • Aclaris Therapeutics names CEO as board chair, COO to take helm
  • Aclaris initiated as a buy at BTIG on potential of zunsemetinib for autoimmune conditions
  • Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata
PEERS

Earnings History

Date EPS / Forecast Revenue / Forecast
February 24, 2022 -0.37 / -0.365 1.5M / 1.79M
November 2, 2021 -0.35 / -0.2817 1.66M / 1.77M
August 5, 2021 -0.34 / -0.275 1.8M / 1.75M Beat!
May 7, 2021 -0.57 / -0.304 1.78M / 1.48M Beat!
March 23, 2021 - / -0.3075 - / 1.39M
February 25, 2021 -0.3 / -0.3075 1.58M / 1.39M Beat!
November 4, 2020 -0.25 / -0.3125 1.45M / 1.47M
August 7, 2020 -0.28 / -0.36 2.05M / 1.23M Beat!
May 7, 2020 -0.37 / -0.38 1.41M / 1.13M Beat!
February 25, 2020 -0.45 / -0.04 1.1M / 9.8M
November 7, 2019 -1.34 / -0.69 983K / 5.92M Beat!
August 8, 2019 -1.21 / -0.76 5.87M / 5.55M Beat!
May 8, 2019 -0.91 / -0.73 5.04M / 4.81M Beat!
March 18, 2019 -0.87 / -0.92 3.67M / 3.73M
November 6, 2018 -1.06 / -1.14 1.63M / 1.75M
August 3, 2018 -1.01 / -1.01 3.68M / 2.07M Beat!
May 8, 2018 -0.98 / -0.97 1.12M / 1M Beat!
November 7, 2017 -0.63 / -0.86 684.0K / 875.0K
August 8, 2017 -0.56 / -0.86 - / -
May 9, 2017 -0.48 / -0.68 - / -
March 15, 2017 -0.49 / -0.6 - / -
November 3, 2016 -0.50 / -0.62 - / -
August 11, 2016 -0.62 / -0.64 - / -
Date Price Open High Low Vol Change ER
Oct 9, 2023 5.76 6.05
6.07
5.69
713K -4.95%
Oct 6, 2023 6.06 5.91
6.13
5.69
521K 2.36%
Oct 5, 2023 5.92 5.99
6.06
5.89
671K -1.66%
Oct 4, 2023 6.02 6.2
6.25
5.98
756K -3.83%
Oct 3, 2023 6.26 6.8
6.98
6.18
1.2M -3.54%
 
Oct 2, 2023 6.49 6.83
6.9
6.29
844K -5.26%
Sep 29, 2023 6.85 6.85
6.92
6.58
867K 1.18%
Sep 28, 2023 6.77 6.63
6.9
6.6
1.2M 1.65%
Sep 27, 2023 6.66 6.64
6.93
6.54
957K 0.45%
Sep 26, 2023 6.63 6.57
6.84
6.38
578K 1.07%
Sep 25, 2023 6.56 6.64
6.72
6.24
1.9M -1.35%
Sep 22, 2023 6.65 6.86
6.86
6.47
1.0M -2.49%
Sep 21, 2023 6.82 6.67
6.96
6.49
831K 0.74%
Sep 20, 2023 6.77 7.4
7.47
6.68
1.2M -8.51%
Sep 19, 2023 7.4 7.42
7.52
7.32
587K -0.4%
Sep 18, 2023 7.43 7.54
7.54
7.15
1.0M -1.59%
Sep 15, 2023 7.55 8
8.18
7.45
1.1M -5.63%
Sep 14, 2023 8 7.94
8.27
7.73
2.2M 5.54%
Sep 13, 2023 7.58 7.64
7.78
7.55
689K -1.3%
Sep 12, 2023 7.68 7.8
7.91
7.61
376K -1.92%
Sep 11, 2023 7.83 7.75
7.98
7.72
1.9M 0.51%
Sep 8, 2023 7.79 7.69
8.22
7.64
672K 2.91%
Sep 7, 2023 7.57 7.51
7.63
7.43
470K 0.26%
Sep 6, 2023 7.55 8.03
8.03
7.45
853K -4.67%
Sep 5, 2023 7.92 7.88
8.24
7.81
814K 0.25%
Sep 1, 2023 7.9 7.53
8.15
7.46
1.0M 5.61%
Aug 31, 2023 7.48 7.5
7.69
7.39
1.2M -0.27%
Aug 30, 2023 7.5 7.57
8.09
7.47
1.9M -1.19%
Aug 29, 2023 7.59 6.8
7.86
6.76
1.2M 15%
Aug 28, 2023 6.6 6.95
7.04
6.52
773K -4.35%
Aug 25, 2023 6.9 7.01
7.17
6.78
651K -1.57%
Aug 24, 2023 7.01 7.26
7.27
6.85
426K -3.58%
Aug 23, 2023 7.27 7.56
7.68
7.26
442K -3.58%
Aug 22, 2023 7.54 7.4
7.73
7.31
1.3M 2.72%
Aug 21, 2023 7.34 7.14
7.45
7.14
448K 2.66%
Aug 18, 2023 7.15 7.09
7.39
7.02
695K -0.14%
Aug 17, 2023 7.16 7.72
7.83
7.15
589K -7.25%
Aug 16, 2023 7.72 7.75
7.99
7.46
684K -0.64%
Aug 15, 2023 7.77 7.94
8.07
7.69
438K -2.39%
Aug 14, 2023 7.96 8.16
8.2
7.94
989K -3.16%
Aug 11, 2023 8.22 8.32
8.45
8.21
374K -1.44%
Aug 10, 2023 8.34 8.48
8.65
8.32
422K -1.65%
Aug 9, 2023 8.48 8.66
8.76
8.33
559K -2.08%
Aug 8, 2023 8.66 9.11
9.37
8.65
550K -5.25%
Aug 7, 2023 9.14 9.95
9.95
9.09
644K -7.21%
Aug 4, 2023 9.85 9.9
10.15
9.74
820K 0.20%
Aug 3, 2023 9.83 9.59
9.91
9.52
273K 1.44%
Aug 2, 2023 9.69 9.78
9.88
9.62
227K -1.22%
Aug 1, 2023 9.81 9.86
9.96
9.53
557K -0.61%
Jul 31, 2023 9.87 9.83
9.95
9.8
329K 0.51%
Jul 28, 2023 9.82 9.68
9.9
9.68
255K 2.29%
Jul 27, 2023 9.6 9.93
9.98
9.58
292K -2.74%
Jul 26, 2023 9.87 9.76
9.95
9.72
261K 0.71%
Jul 25, 2023 9.8 9.77
10.1
9.71
375K -0.51%
Jul 24, 2023 9.85 10.62
10.72
9.84
567K -7.25%
Jul 21, 2023 10.62 10.49
10.77
10.44
576K 1.72%
Jul 20, 2023 10.44 10.45
10.6
10.34
374K 0.10%
Jul 19, 2023 10.43 10.67
10.74
10.4
659K -2.43%
Jul 18, 2023 10.69 10.88
11.07
10.6
437K -1.84%
Jul 17, 2023 10.89 10.93
11.12
10.84
534K 0%